ACT-064992 / JNJ-67896062 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension1

86. Pulmonary arterial hypertension


Clinical trials : 1,181 Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-001062-28-PL
(EUCTR)
06/03/2018A study to find out whether the medicine macitentan works in children with pulmonary arterial hypertension (PAH)A multicenter, open-label, randomized, study with single-arm extension period to assess the pharmacokinetics, safety and efficacy of macitentan versus standard of care in children with pulmonary arterial hypertension - TOMORROW: pediaTric use Of Macitentan tO delay disease pRogRessiOn in PAH Worldwide Pulmonary arterial hypertension
MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: macitentan
Product Code: ACT-064992 / JNJ-67896062
INN or Proposed INN: MACITENTAN
Product Name: macitentan
Product Code: ACT-064992 / JNJ-67896062
INN or Proposed INN: MACITENTAN
Product Name: macitentan
Product Code: ACT-064992 / JNJ-67896062
INN or Proposed INN: MACITENTAN
Product Name: macitentan
Product Code: ACT-064992 / JNJ-67896062
INN or Proposed INN: MACITENTAN
Product Name: macitentan
Product Code: ACT-064992 / JNJ-67896062
INN or Proposed INN: MACITENTAN
ACTELION Pharmaceuticals LtdNULLNAFemale: yes
Male: yes
300Phase 3Portugal;United States;Philippines;Finland;Spain;Thailand;Ukraine;Austria;Israel;Russian Federation;Colombia;France;Hungary;Mexico;Canada;Poland;Brazil;Malaysia;Viet Nam;Australia;South Africa;China;Korea, Republic of